Stephen Doster
-
Novel methods to treat glaucoma
Glaucoma is characterized by degeneration of retinal ganglion cells, leading to irreversible vision loss. Currently, the only treatable glaucoma risk factor is increased intraocular pressure. While lowering this pressure can slow vision loss, it does not completely halt progression of the disease. Therefore, determining more direct mechanisms to prevent retinal… Read MoreNov. 8, 2018
-
Obesity negates beneficial drug effects
Blocking CETP — a protein that shuttles cholesterol and triglycerides between lipoproteins such as HDL and LDL — has been shown to improve levels of the “good” cholesterol HDL. Outcomes from clinical trials of CETP inhibitors, however, have not demonstrated robust decreases in the risk of cardiovascular disease. Because many participants… Read MoreNov. 8, 2018
-
Team’s findings show glutamine metabolism affects T cell signaling
The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered. They show that a drug that inhibits glutamine metabolism — currently in clinical trials as an anticancer agent — might also be useful as a… Read MoreNov. 2, 2018
-
Exploring Single Cell Data with sc-UniFrac
Our growing ability to acquire data at the level of single cells in complex samples provides exciting new opportunities to understand physiological and pathophysiological processes; however, it also presents daunting challenges for the statistical evaluation of the resultant huge datasets. To date, most experimental approaches have focused on identifying the… Read MoreOct. 25, 2018
-
Rothamel selected as Vanderbilt Prize Student Scholar
Katherine Rothamel, a PhD student in the Department of Biochemistry at Vanderbilt University School of Medicine, has been selected as the 2017 Vanderbilt Prize Student Scholar. Katherine Rothamel She will be mentored by Lynne Maquat, PhD, an internationally known scientist at the University of Rochester School of Medicine and… Read MoreOct. 25, 2018
-
Grant enhances study of new chemotherapy targets
Vanderbilt chemists have been awarded $7.2 million over the next five years from the National Cancer Institute to lead an initiative to better understand how a combination chemotherapy for breast cancer targets DNA. Michael Stone, PhD, Carmelo Rizzo, PhD, and Martin Egli, PhD, will research the chemical biology… Read MoreOct. 23, 2018
-
Cellular stress defense
Small heat-shock proteins (sHSPs) are molecular chaperones that bind to unfolded proteins to prevent protein aggregation and defend against cellular stress. Mutations in human sHSPs are associated with inherited diseases including cataract and cardiomyopathy. Individual sHSPs bind to each other to form oligomers. Hassane Mchaourab,… Read MoreOct. 23, 2018
-
Targeting diabetic kidney disease
Diabetic nephropathy (DN) is a kidney disease characterized by loss of kidney function in patients with diabetes. Raymond Harris, MD, and colleagues previously showed that the epidermal growth factor receptor (EGFR) is activated in mouse models of type 1 diabetes, and that… Read MoreOct. 23, 2018
-
Novel genetic study sheds new light on risk of heart attack
Loss of a protein that regulates mitochondrial function can greatly increase the risk of myocardial infarction (heart attack), Vanderbilt scientists reported Oct. 3 in the journal eLife. The study illustrates how “integrative genomics,” a combination of basic research, a human biobank linked to electronic health records… Read MoreOct. 12, 2018
-
Cancer Center investigators awarded Komen grants
Four Vanderbilt-Ingram Cancer Center (VICC) investigators have received financial support from Susan G. Komen for breast cancer research. Jennifer Pietenpol, PhD, Executive Vice President for Research at Vanderbilt University Medical Center (VUMC) and director of VICC, will receive $400,000 to lead a clinical trial for patients with metastatic triple-negative breast… Read MoreOct. 12, 2018